Fighting against resistant strains: the case of benzothiazinones and dinitrobenzamides

The resurgence of tuberculosis is ascribed to co-infection with immunodeficiency virus, and the emergence of Mycobacterium tuberculosis drug-resistant strains. New molecules should be useful to fight both drug-susceptible as well as drug-resistant strains. The two principal research routes to find out new antibacterial molecules and novel bacterial targets are from drug to target and from target to drug. Until now the first one appears to be the most easily attainable, leading to the discovery of new molecules which are currently in clinical trials and the last published benzothiazinones and dinitrobenzamides.